Tadalafil for Female Sexual Arousal Disorder: Restore Intimacy and Confidence

Tadalafil, commonly recognized for its use in treating male erectile dysfunction, has emerged as a significant therapeutic option for premenopausal women diagnosed with Female Sexual Arousal Disorder (FSAD). This product card provides a comprehensive, evidence-based overview of its application, mechanism, and clinical considerations. As a phosphodiesterase type 5 (PDE5) inhibitor, tadalafil enhances blood flow to genital tissues, addressing physiological aspects of arousal inadequacy that may not respond to psychological interventions alone. It is prescribed under strict medical supervision following a thorough diagnostic evaluation to rule out contraindications and ensure appropriate patient selection.

Features

  • Active ingredient: Tadalafil
  • Standard dosage forms: 5mg, 10mg, and 20mg oral tablets
  • Pharmacological class: Phosphodiesterase type 5 (PDE5) inhibitor
  • Onset of action: Typically within 30–60 minutes post-administration
  • Duration of effect: Up to 36 hours, allowing for spontaneity
  • Prescription status: Available only with a valid physician’s prescription

Benefits

  • Improves genital blood flow and sensitivity, directly targeting physiological barriers to arousal
  • Enhances the possibility of achieving satisfactory sexual experiences, contributing to emotional well-being
  • Supports relationship intimacy by reducing anxiety and performance-related stress
  • Offers a extended window of effectiveness, reducing time-sensitive pressure
  • May be used as an adjunct to sex therapy or counseling for holistic management
  • Provides a evidence-based option for women who have not responded to non-pharmacological treatments

Common use

Tadalafil is indicated for the treatment of Female Sexual Arousal Disorder (FSAD) in premenopausal women. FSAD is characterized by a persistent or recurrent inability to attain or maintain sufficient sexual excitement, causing personal distress. It is not intended for use in postmenopausal women or for enhancing sexual function in individuals without a diagnosed disorder. Diagnosis should be made by a healthcare provider specializing in sexual medicine, and treatment should be part of a comprehensive management plan that may include psychological support.

Dosage and direction

The typical starting dose for FSAD is 10mg, taken orally approximately 30–60 minutes before anticipated sexual activity. Based on efficacy and tolerability, the dose may be adjusted to a maximum of 20mg or reduced to 5mg. It should not be taken more than once per day. Tadalafil may be taken with or without food, though high-fat meals may delay absorption. Sexual stimulation is required for the medication to be effective. Do not crush or split tablets unless advised by a physician.

Precautions

  • A comprehensive medical and sexual history must be obtained before prescription.
  • Use with caution in patients with cardiovascular risk factors; sexual activity may pose cardiac risk.
  • Not recommended for use with other treatments for sexual dysfunction unless supervised by a physician.
  • Avoid consumption of grapefruit or grapefruit juice, as it may increase tadalafil concentrations.
  • Use in women with anatomical genital anomalies or history of priapism (although rare in women) requires careful evaluation.
  • Regular follow-ups are necessary to assess treatment response and side effects.

Contraindications

  • Hypersensitivity to tadalafil or any component of the formulation.
  • Concurrent use of nitrates or nitric oxide donors in any form.
  • Use with guanylate cyclase stimulators such as riociguat.
  • Severe hepatic impairment (Child-Pugh Class C).
  • Unstable angina, recent myocardial infarction, or uncontrolled hypotension.
  • History of non-arteritic anterior ischemic optic neuropathy (NAION).

Possible side effect

Common side effects may include headache, flushing, dyspepsia, nasal congestion, back pain, and myalgia. These are generally mild to moderate and transient. Less frequently reported effects include dizziness, visual changes, and palpitations. Although rare, serious adverse effects such as sudden hearing loss, prolonged erection (priapism), or severe hypotension may occur and require immediate medical attention.

Drug interaction

Tadalafil is primarily metabolized by CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase tadalafil exposure—dose adjustment is necessary. Alpha-blockers and antihypertensives may potentiate hypotensive effects. Avoid concurrent use with nitrates due to risk of severe hypotension. Other PDE5 inhibitors should not be used simultaneously.

Missed dose

Tadalafil is taken on an as-needed basis. If a dose is missed, it may be taken when remembered, provided sufficient time remains before sexual activity. Do not take a double dose to make up for a missed one.

Overdose

In case of suspected overdose, symptoms may include severe headache, dizziness, fainting, or prolonged erection. Seek immediate medical attention. Supportive measures should be implemented, including monitoring of vital signs. Hemodialysis is not expected to significantly accelerate elimination.

Storage

Store at room temperature (15–30°C or 59–86°F) in a tightly closed container, away from light, moisture, and heat. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication or treatment plan. Individual responses to medication may vary.

Reviews

Clinical studies and patient reports indicate that tadalafil can be effective for a subset of women with FSAD, particularly those with noted vascular insufficiency. Satisfaction is often correlated with comprehensive diagnostic and therapeutic support. Some users report significant improvement in arousal and overall sexual satisfaction, while others may experience limited benefit or side effects. Long-term data remains limited, and ongoing research is essential to optimize use.

More info: